CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

Placebo-controlled results from the RewinD-LB clinical trial, published in Alzheimer's Research & Therapy, provide further evidence that neflamapimod may slow clinical disease progression in dementia with Lewy bodies (DLB). The article excerpt gives no effect size, trial results detail, or market reaction.